Comprehensive genomic profiling

DIAGNOSTIC_TEST2 trials

Sponsors

Medical University of Vienna, The Belgian Society of Medical Oncology

Conditions

Advanced LymphomaMetastatic CancerRefractory Acute Myeloid LeukemiaRefractory LeukemiaRefractory LymphomaRefractory T-Cell LymphomaSolid Tumor

Unknown Phase

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

RecruitingNCT04470947

Medical University of ViennaAdvanced Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Leukemia +2

Start: 2020-06-10End: 2026-03-31Target: 150Updated: 2024-03-22

A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre

RecruitingNCT05058937

The Belgian Society of Medical OncologyMetastatic Cancer, Solid Tumor

Start: 2021-06-01End: 2026-05-31Target: 936Updated: 2021-09-28

Related Papers

Comparing functional and genomic‐based precision medicine in blood cancer patients

HemaSphere2025-04-012 citations

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

Blood2023-11-025 citations

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Blood2020-11-042 citations